| Literature DB >> 20479975 |
Prabha Devi1, Solimabi Wahidullah, Cheryl Rodrigues, Lisette D Souza.
Abstract
Several bacterial cultures were isolated from sponge Halichondria sp., collected from the Gujarat coast of the Indo Pacific region. These bacterial cultures were fermented in the laboratory (100 mL) and the culture filtrate was assayed for antibiotic activity against 16 strains of clinical pathogens. Bacillus sp. (SAB1), the most potent of them and antagonistic to several clinically pathogenic Gram-positive, Gram-negative bacteria and the fungus Aspergillus fumigatus was chosen for further investigation. Analysis of the nucleotide sequence of the 16S rDNA gene of Bacillus sp. SAB1 showed a strong similarity (100%) with the 16S rDNA gene of Bacillus licheniformis HNL09. The bioactive compounds produced by Bacillus licheniformis SAB1 (GenBank accession number: DQ071568) were identified as indole (1), 3-phenylpropionic acid (2) and a dimer 4,4'-oxybis[3-phenylpropionic acid] (3) on the basis of their Fourier Transform Infrared (FTIR), Nuclear Magnetic Resonance (NMR) and Electrospray Ionization Mass Spectrometer (ESI-MS) data. There is a single reference on the natural occurrence of compound 3 from the leaves of a terrestrial herb Aptenia cordifolia in the literature, so to the best of our knowledge, this is a first report of its natural occurrence from a marine source. The recovery of bacterial strains with antimicrobial activity suggests that marine-invertebrates remain a rich source for the isolation of culturable isolates capable of producing novel bioactive secondary metabolites.Entities:
Keywords: Bacillus licheniformis; antibiotic activity; associated bacteria; secondary metabolites; sponge
Mesh:
Substances:
Year: 2010 PMID: 20479975 PMCID: PMC2866483 DOI: 10.3390/md8041203
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
List of clinical pathogens used for antibiotic screening.
| Sr. No. | Isolate no. | Nature of pathogen | Name of pathogen | Disease it causes |
|---|---|---|---|---|
| 1. | B1 | Bacterial pathogens | Gastrointestinal infection | |
| 2. | B2 | Urinary tract infection | ||
| 3. | B3 | Skin infection | ||
| 4. | B4 | Typhoid | ||
| 5. | B5 | Gastrointestinal infection | ||
| 6. | B6 | Urinary tract infection | ||
| 7. | B7 | Cholera | ||
| 8. | F1 | Fungal pathogens | Skin infection | |
| 9. | F2 | Skin infection | ||
| 10. | F3 | Candidiasis | ||
| 11. | F4 | Skin infection | ||
| 12. | F5 | Skin infection | ||
| 13. | D1 | Multi-drug resistant bacteria | Skin infection | |
| 14. | D2 | Urinary tract infection | ||
| 15. | D3 | Typhoid | ||
| 16. | D4 | Methicillin Resistant | Skin infection |
1H- and 13C-NMR data of Compounds 1, 2 and 3.
| Compound 1: indole | Compound 2: 3-phenylpropionic acid | Compound 3: 4,4′-oxybis(3-phenylpropionic acid) | ||||||
|---|---|---|---|---|---|---|---|---|
| Position | 1HNMR | 13CNMR | Position | 1HNMR | 13CNMR | Position | 1HNMR | 13CNMR |
| 1 | 8. 13 (b,s) | - | 1 | - | 179.45 | 1,1′ | - | 132.46 |
| 2 | 7. 64 (d, 7.5Hz) | 124.13 | 2 | 2.96(t,7.5,7.8Hz) | 35.61 | 2,6,2′,6′ | 7.07(d, 8.4Hz) | 115.43 |
| 3 | 7. 28 (d, 7.8Hz) | 121.89 | 3 | 2.68(t, 7.5,7.8Hz) | 30.54 | 3,5,3′,5′ | 6.75(d, 8.4Hz) | 129.48 |
| 4 | 6. 55 (s) | 102.42 | 1′ | - | 140.13 | 4,4′ | - | 154.11 |
| 5 | 7.09–7.23 (3H, m) | 120.65 | 2′,6′ | 7.19–7.38(5H,m) | 128.54 | 7,7′ | 2.89(t, 7.5,7.8Hz) | 29.88 |
| 6 | 119.74 | 3′,5′ | 128.24 | 8,8′ | 2.64(t, 7.5,7.8Hz) | 34.49 | ||
| 7 | 111.01 | 4′ | 126.38 | |||||
| 8 | 135.69 | |||||||
| 9 | 127.76 | |||||||
Antibiotic activity of crude, and pure compounds (Comp 1- indole; Comp 2 – 3-phenylpropionic acid; Comp 3- 4,4′-oxybis(3-phenylpropionic acid) isolated from Bacillus licheniformis SAB1.
| No. | Pathogens used for study | Crude Extract (100μg/disc) | Comp 1 (50μg/disc) | Comp 2 (50μg/disc) | Comp 3 (50μg/disc) | STD Antibiotics (50μg/disc) | Solvent Methanol |
|---|---|---|---|---|---|---|---|
| B1 | - | - | - | - | ++++ | - | |
| B2 | +++ | ++ | ++ | - | +++++ | - | |
| B3 | ++ | +++ | ++ | - | +++ | - | |
| B4 | + | +++ | ++ | ++ | ++ | - | |
| B5 | - | - | - | - | +++++ | - | |
| B6 | - | - | - | - | +++++ | - | |
| B7 | + | - | - | ++ | +++++ | - | |
| D1 | + | + | ++ | - | ++ | - | |
| D2 | + | + | ++ | - | - | - | |
| D3 | - | - | - | - | - | - | |
| D4 | Methicillin Resistant | + | ++ | ++ | - | ++ | - |
| F1 | ++ | - | - | +++ | ++++ | - | |
| F2 | + | ++ | +++ | - | - | - | |
| F3 | + | +++ | ++ | - | - | - | |
| F4 | + | + | ++ | - | - | - | |
| F5 | - | - | - | - | - | - |
- no zone of growth inhibition;
+ 1–3mm zone of inhibition;
++ 4–6mm zone of inhibition;
+++ 7–10mm zone of inhibition;
++++ 11–15mm zone of inhibition;
+++++ 16–22mm zone of inhibition; Antibiotics: Streptomycin/Ketoconazole.